Filters

Anti-cdc2 (Thr14) (Polyclonal), ALEXA Fluor 594

Anti-cdc2 (Thr14) (Polyclonal), ALEXA Fluor 594 size: 100 microliters 516

Supplier BIOSS POLYCLONAL ANTIBODIES
Price 516
Size 100 microliters
Contact us Ask Component cell markers and DNA bp. markers are genetic markerser genes or DNA sequenceswith selection audit
TypeConjugated Primary Antibody
Conjugated with 594, ALEXA FLUOR®
Host organismRabbit (Oryctolagus cuniculus)
Target Protein/Peptidecdc2 Thr14
SpecificityThis antibody reacts specifically with cdc2 (Thr14)
ModificationPhosphorylation
Modification siteThr14
ClonalityPolyclonal Antibody
ClonePolyclonal Antibodies
Concentration1ug per 1ul
Subcellular locationsN/A
Antigen SourceKLH conjugated synthetic phosphopeptide derived from human cdc2 around the phosphorylation site of Thr14 [EG(p-T)YG]
Gene ID983
Swiss ProtN/A
ApplicationsIF(IHC-P)
Applications with corresponding dilutionsIF(IHC-P)(1:50-200)
Cross reactive species Mouse (Mus musculus), Rat (Rattus norvegicus), Human (Homo sapiens)
Cross Reactive Species details However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species, No significant cross reactivity has been observed for this antibody for the tested species
Background information Activation of Cdc2 is controlled at several steps including cyclin binding and phosphorylation of threonine 161, Cdc2 exists as a complex with both cyclin A and cyclin B, Furthermore, However, Phosphorylation at Tyr15 and inhibition of Cdc2 is carried out by WEE1 and MIK protein kinases while Tyr15 dephosphorylation and activation of Cdc2 is carried out by the cdc25 phosphatase, The best characterized of these associations is the Cdc2 p34 cyclin B complex, The isoform CDC2deltaT is found in breast cancer tissues, also known as cyclin dependent kinase 1 (Cdk1) or p34/cdk1, cdc2/Cdk1 is a key mediator of neuronal cell death in brain development and degeneration, plays a key role in the control of the eukaryotic cell cycle, the critical regulatory step in activating cdc2 during progression into mitosis appears to be dephosphorylation of Tyr15 and Tyr14, where it is required for entry into S phase and mitosis, which is required for the G2 to M phase transition, The cell division control protein cdc2
Purification methodPurified by Protein A
Storage 50% glycerol and 0, Store at 4°, 09% sodium azide, C for 12 months, Water buffered solution containing 100ug/ml BSA
Excitation emission590nm/617nm
Synonyms CDK 1, CDK1, Cdc 2, Cell Divsion Cycle 2 Protein, Cell division control protein 2, Cell division control protein 2 homolog, Cell division cycle 2 G1 to S and G2 to M, P34CDC2
Also known ascdc2 (Thr14) Polyclonal Antibody
Other nameAnti-cdc2 (Thr14) Polyclonal
Advisory For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube, Prior to use briefly centrifuge the vial to gather all the solution on the bottom, specificity and sensitivity, thus reducing its reactivity, Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody
PropertiesFor facs or microscopy Alexa 1 conjugate
ConjugationAlexa Fluor
GroupPolyclonals and antibodies
About The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera, immunohistochemistry on frozen slices or parrafin fixed tissues, Polyclonals can be used for Western blot
Gene targetcdc2 (Thr14)
Short nameAnti-cdc2 (Thr14) (Polyclonal) Fluor 594
Technique Pabs are a collection of immunoglobulin , Polyclonal antibodies , each identifying a different , whereas , (pAbs) are mostly rabbit or goat , B cells, Polyclonal, antibodies , antigen, come from a single N cell lineage, epitope, molecules that react against a specific , monoclonal antibodies , that are secreted by different 
LabelALEXA
Alternative name ALEXA Fluor 594, antibody to-cdc2 (Thr14) (polyclonal)
Alternative techniquepolyclonals

Similar products

Subscribe to our Newsletter